ClinicalTrials.gg
RecruitingNCT07130318Updated Aug 19, 2025

Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise

An interventional study of exercise plus diet restriction and diet restriction in Familial Mediterranean Fever and Non-Alcoholic Fatty Liver Disease, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to female participants aged 30 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled May 2025, registered Aug 2025).
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
30 Years to 55 Years
Sex
Female
01

Study summary

Familial Mediterranean fever (FMF) affect liver and causes some dysfunctions including non-alcoholic fatty liver.. still exercise and diet limitation is the treatment for this case

Read the detailed description

Familial Mediterranean fever (FMF women with fatty liver) will be collected to be cateogarized to group I or group II. Every group OF FMF will contain 20 FMF women. Both groups will follow their colchicine (traditional daily drug therapy for FMF) in addition to Mediterranean diet for six months. Group I will also perform elliptical aerobic exercise (this exercise will be applied for 40 minutes three times weekly and this exercise will be maintained for 6 months)

02

Conditions studied

  • Familial Mediterranean Fever
  • Non-Alcoholic Fatty Liver Disease
03

In context

Familial Mediterranean Fever

61 studies on the registry are indexed under Familial Mediterranean Fever; 27 are open to participants now.

This study's planned enrollment of 40 is close to the median of 40 across 27 interventional studies indexed under Familial Mediterranean Fever.

Browse Familial Mediterranean Fever studies →

Lead sponsor

Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • familial Mediterrean fever women
  • obese women
  • women who have fatty live (non alcoholic type)

Exclusion criteria

Exclusion Criteria:

  • cardiac patients
  • respiratory disease
  • renal disease
  • cancer
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    group number 1

    Familial Mediterranean fever (FMF women ) will be collected in this group. the group OF FMF will contain 20 FMF women. the group will follow their colchicine (traditional daily drug therapy for FMF) in addition to Mediterranean diet for six months. also, this group, Group I, will also perform elliptical aerobic exercise (this exercise will be applied for 40 minutes three times weekly and this exercise will be maintained for 6 months)

    Behavioral: exercise plus diet restriction

  • Active comparator
    group number 2

    Familial Mediterranean fever (FMF women ) will be collected in this group. the group OF FMF will contain 20 FMF women. the group will follow their colchicine (traditional daily drug therapy for FMF) in addition to Mediterranean diet for six months.

    Behavioral: diet restriction

Interventions

  • Behavioralexercise plus diet restriction

    Familial Mediterranean fever (FMF women ) will be collected in this group. the group OF FMF will contain 20 FMF women. the group will follow their colchicine (traditional daily drug therapy for FMF) in addition to Mediterranean diet for six months. also, this group, Group I, will also perform elliptical aerobic exercise (this exercise will be applied for 40 minutes three times weekly and this exercise will be maintained for 6 months)

  • Behavioraldiet restriction

    Familial Mediterranean fever (FMF women ) will be collected in this group. the group OF FMF will contain 20 FMF women. the group will follow their colchicine (traditional daily drug therapy for FMF) in addition to Mediterranean diet for six months.

06

What researchers measure

Primary outcomes

  1. aspartate transaminase

    it is a hepatic enzyme

    Time frame: it will be measured after 6 months

Secondary outcomes

  1. alanine transaminase

    it is a hepatic enzyme

    Time frame: it will be measured after 6 months

  2. body mass index

    it will be measured after patient emptying his bowel and bladder

    Time frame: it will be measured after 6 months

  3. waist circumference

    it will be measured at umbilical level

    Time frame: it will be measured after 6 months

  4. high density lipoprotein

    it will be measured in plasma

    Time frame: it will be measured after 6 months

  5. triglycerides

    it will be measured in plasma

    Time frame: it will be measured after 6 months

  6. cholesterol

    it will be measured in plasma

    Time frame: it will be measured after 6 months

  7. low density lipoprotein

    it will be measured in plasma

    Time frame: it will be measured after 6 months

  8. c reactive protein

    it will be measured in plasma

    Time frame: it will be measured after 6 months

  9. erythrocyte sedimentation rate

    it will be measured in plasma

    Time frame: it will be measured after 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Jan 2026, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Aug 19, 2025
StartActual
May 8, 2025
Primary completionEst.
Jan 8, 2026
CompletionEst.
Jan 8, 2026
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07130318
Lead sponsor
Cairo University
Responsible party
Ali Mohamed Ali ismail (lecturer of physical therapy for Cardiovascular, Respiratory disorder and Geriatrics, Faculty of Physical Therapy, Cairo University, Cairo University) — Principal investigator
First posted
Aug 19, 2025
Start date
May 8, 2025
Primary completion
Jan 8, 2026 (estimated)
Completion
Jan 8, 2026 (estimated)
Last update
Aug 19, 2025

Study contacts

Ali MA Ismail, lecturer
Contact
ali.mohamed@pt.cu.edu.eg
01005154209
Ali Ismail, lecturer
Contact
allooka2012@gmail.com
Ali MA Ismail, lecturer
principal investigator · Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion